WallStSmart

Forian Inc (FORA)vsMiniMed Group, Inc. Common Stock (MMED)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

MiniMed Group, Inc. Common Stock generates 10168% more annual revenue ($2.89B vs $28.11M). FORA leads profitability with a -3.0% profit margin vs -7.3%. FORA earns a higher WallStSmart Score of 39/100 (F).

FORA

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 5.0

MMED

Hold

37

out of 100

Grade: F

Growth: 5.3Profit: 3.5Value: 5.0Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FORA3 strengths · Avg: 8.7/10
Revenue GrowthGrowth
65.6%10/10

Revenue surging 65.6% year-over-year

PEG RatioValuation
0.948/10

Growing faster than its price suggests

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

MMED0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

FORA4 concerns · Avg: 2.3/10
Market CapQuality
$64.63M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-2.9%2/10

ROE of -2.9% — below average capital efficiency

EPS GrowthGrowth
-89.1%2/10

Earnings declined 89.1%

Free Cash FlowQuality
$-439,6662/10

Negative free cash flow — burning cash

MMED4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Operating MarginProfitability
1.4%3/10

Operating margin of 1.4%

Free Cash FlowQuality
$-53.00M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : FORA

The strongest argument for FORA centers on Revenue Growth, PEG Ratio, Price/Book. Revenue growth of 65.6% demonstrates continued momentum. PEG of 0.94 suggests the stock is reasonably priced for its growth.

Bull Case : MMED

Revenue growth of 13.1% demonstrates continued momentum.

Bear Case : FORA

The primary concerns for FORA are Market Cap, Return on Equity, EPS Growth.

Bear Case : MMED

The primary concerns for MMED are EPS Growth, Return on Equity, Operating Margin.

Key Dynamics to Monitor

FORA profiles as a hypergrowth stock while MMED is a turnaround play — different risk/reward profiles.

FORA is growing revenue faster at 65.6% — sustainability is the question.

FORA generates stronger free cash flow (-439,666), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

FORA scores higher overall (39/100 vs 37/100) and 65.6% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Forian Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Forian Inc. provides a suite of software solutions, data management capabilities, proprietary data, and predictive analytics to optimize and measure operational, clinical, and financial performance for clients in the health and cannabis industries, as well as dispensaries. , cannabis growers, manufacturers, and distributors. The company is headquartered in Newtown, Pennsylvania.

MiniMed Group, Inc. Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Minimed Group, Inc. is a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company is headquartered in Northridge, California.

Want to dig deeper into these stocks?